Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A8KQ
|
|||
| Former ID |
DNCL003601
|
|||
| Drug Name |
GSK2256294
|
|||
| Synonyms |
GSK-2256294
Click to Show/Hide
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H24F3N7O
|
|||
| Canonical SMILES |
CC1=NC(=NC(=N1)NC2CCCC(C2)C(=O)NCC3=C(C=C(C=C3)C#N)C(F)(F)F)NC
|
|||
| InChI |
1S/C21H24F3N7O/c1-12-28-19(26-2)31-20(29-12)30-16-5-3-4-14(9-16)18(32)27-11-15-7-6-13(10-25)8-17(15)21(22,23)24/h6-8,14,16H,3-5,9,11H2,1-2H3,(H,27,32)(H2,26,28,29,30,31)/t14-,16+/m1/s1
|
|||
| InChIKey |
LQHDJQIMETZMPH-ZBFHGGJFSA-N
|
|||
| CAS Number |
CAS 1142090-23-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Soluble epoxide hydrolase (EPHX2) | Target Info | Modulator | [1], [2] |
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Metapathway biotransformation | |||
| Arachidonate Epoxygenase / Epoxide Hydrolase | ||||
| Arachidonic acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301. | |||
| REF 2 | In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.